UNSPSC 51283221: Spiramycin adipate

This classification denotes a macrolide antibiotic with the molecular formula C49H84N2O18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L9KNT101OK, chemically known as hexanedioic acid, compd. with spiramycin (1:1), but more generally known as spiramycin adipate, which bears US NIH Compound Identifier 6450354. European Medicines Agency schedules spiramycin adipate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04526MIG.

Most nations, for tariff purposes, schedule spiramycin adipate under HS 29419000. SMILES:.

UNSPSC 51283221 Spiramycin adipate is a Commodity code that in practice captures pharmaceutical procurement by state and local health agencies, though the recent opportunities block shows limited activity directly under this specific antibiotic designation. State and local governments use codes in this family to procure branded and generic pharmaceuticals for public health stockpiling, emergency preparedness, and community health programs. The issuing bodies soliciting under related pharmaceutical codes include state departments of public health, county health authorities, and special-purpose districts managing public health initiatives. The scope of work encompasses supply agreements for antibiotics, antivirals, naloxone, and other pharmaceuticals delivered through piggyback contracts tied to cooperative purchasing consortia such as MMCAP Infuse, which allow individual jurisdictions to leverage pre-negotiated master agreements without issuing their own full RFP cycle.

The Illinois Department of Public Health awarded a piggyback pharmaceutical supply contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets totaling $2,999,999.11 over three years; Seminole County, Florida released an IFB in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, though that solicitation carries an anomalous due date of July 2023 and appears to be a historical record. Recent activity concentrates in Florida and Illinois. The pharmaceutical-procurement category shows low-volume solicitation activity under this specific commodity code; vendors pursuing state and local pharmaceutical supply contracts should monitor cooperative purchasing vehicles and state health department acquisition channels rather than expect frequent open solicitations under the individual drug-name codes.